GM-CSF: Clinical Trials

63 trials of GM-CSF, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

42 completed, 7 terminated, 6 recruiting, 6 unknown. 63 Phase 1, 20 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 163Completed 42, Terminated 7, Recruiting 6, Unknown 6, Active not recruiting 1, Withdrawn 1
Phase 220Completed 15, Unknown 3, Recruiting 1, Withdrawn 1

Follow GM-CSF: new trials by email Literature Review of GM-CSF trials Research Report on GM-CSF

Trials (filtered) newest first · largest first

All 63 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF - Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma
Phase 1RecruitingMedical College of Wisconsin422026-03-042026-04-03
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Phase 1RecruitingDavid Avigan302026-02-122026-05-05
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
DC/MM Fusion Vaccine, GM-CSF - Multiple Myeloma, Refractory Multiple Myeloma
Phase 1RecruitingDavid Avigan252026-01-302026-05-08
Tebentafusp-tebn With LDT in Metastatic UM
Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU - Metastatic Uveal Melanoma
Phase 1 / Phase 2RecruitingThomas Jefferson University1092025-10-152026-07-21
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Elranatamab, GM-CSF, DC/MM Fusion Vaccine - Multiple Myeloma, Relapse Multiple Myeloma
Phase 1RecruitingDavid Avigan252025-01-312026-05-07
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
iNeo-Vac-P01, GM-CSF - Resectable Esophageal Cancer
Phase 1Active not recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine272021-12-022025-12-02
GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery
GM-CSF, fosfomycin and metronidazole - Pouchitis
Phase 1 / Phase 2UnknownZealand University Hospital182021-09-062023-01-26
IBI188 Combination Therapy in Solid Tumors
IBI188, GM-CSF, Cisplatin/Carboplatin - Solid Tumors, Lung Adenocarcinoma
Phase 1TerminatedInnovent Biologics (Suzhou) Co. Ltd.92021-05-252022-10-04
Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
iNeo-Vac-P01, GM-CSF - Resectable Pancreatic Cancer
Phase 1UnknownZhejiang Provincial People's Hospital202021-03-302021-11-16
Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection
AV-COVID-19, GM-CSF - COVID-19
Phase 1CompletedAivita Biomedical, Inc.272020-12-072021-12-16
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Abemaciclib, Irinotecan, Temozolomide - Relapsed Solid Tumor, Refractory Solid Tumor
Phase 1 / Phase 2CompletedEli Lilly and Company472020-11-092026-03-02
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
iNeo-Vac-P01, GM-CSF, PD-1 - Advanced Malignant Solid Tumor
Phase 1UnknownSir Run Run Shaw Hospital302020-09-032021-04-28
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
galinpepimut-S, pembrolizumab, Montanide - Acute Myelogenous Leukemia, Ovarian Cancer
Phase 1 / Phase 2CompletedSellas Life Sciences Group262019-09-302024-11-19
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Galinpepimut-S, Nivolumab, Sargramostim - Mesothelioma, Pleural Mesothelioma
Phase 1CompletedMemorial Sloan Kettering Cancer Center102019-07-242025-05-13
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Granulocyte-Macrophage Colony-Stimulating Factor, Multi-epitope HER2 Peptide Vaccine H2NVAC, Therapeutic Conventional Surgery - Breast Ductal Carcinoma In Situ
Phase 1RecruitingMayo Clinic432019-06-272026-03-05
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
UV1, GM-CSF - Malignant Melanoma
Phase 1CompletedUltimovacs ASA302018-07-092024-08-22
First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699
Placebo, GSK3358699, GM-CSF - Arthritis, Rheumatoid
Phase 1TerminatedGlaxoSmithKline482018-03-132020-12-02
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor
iNeo-Vac-P01, GM-CSF - Advanced Malignant Solid Tumor
Phase 1UnknownSir Run Run Shaw Hospital302018-02-072021-11-16
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
iNeo-Vac-P01, GM-CSF - Pancreatic Cancer, Pancreatic Carcinoma
Phase 1CompletedZhejiang Provincial People's Hospital72017-10-242021-11-16
REO13 Melanoma With of Without GM-CSF
Reolysin, GM-CSF - Melanoma, Cancer of Skin
Phase 1 / Phase 2WithdrawnUniversity of Leeds2017-10-012018-05-04

Showing 20 of 63. Sign in to see all of them.

Conditions studied

Melanoma (11)  ·  Breast Neoplasms (5)  ·  Multiple Myeloma (5)  ·  Lymphoma (4)  ·  Neuroblastoma (4)  ·  Breast Neoplasms, Male (3)  ·  Carcinoma, Ovarian Epithelial (3)  ·  Colorectal Neoplasms (3)  ·  Leukemia (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Pancreatic Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Uveal Melanoma (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Colonic Neoplasms (2)

Sponsors

National Cancer Institute (NCI) (7)  ·  David Avigan (3)  ·  University of Washington (3)  ·  Mayo Clinic (2)  ·  Roger Williams Medical Center (2)  ·  Roswell Park Cancer Institute (2)  ·  Sellas Life Sciences Group (2)  ·  Sir Run Run Shaw Hospital (2)  ·  Ultimovacs ASA (2)  ·  University Hospital Tuebingen (2)  ·  University of Virginia (2)  ·  Zhejiang Provincial People's Hospital (2)  ·  Ahmad Tarhini (1)  ·  Aivita Biomedical, Inc. (1)  ·  Barbara Ann Karmanos Cancer Institute (1)

Countries

United States (45)  ·  China (6)  ·  United Kingdom (4)  ·  Germany (3)  ·  Australia (2)  ·  Belgium (2)  ·  Spain (2)  ·  Sweden (2)  ·  Bulgaria (1)  ·  Denmark (1)  ·  France (1)  ·  Hungary (1)  ·  Indonesia (1)  ·  Italy (1)  ·  Japan (1)

Top investigators

David Avigan, MD (2)  ·  John Marshall (2)  ·  Kunle Odunsi (2)  ·  Abby Maizel, MD, PhD (1)  ·  Abby Maizel, MD,PhD (1)  ·  Ahmad A. Tarhini, MD, MS (1)  ·  Al Barqawi (1)  ·  Amy C. Degnim, M.D. (1)  ·  Andrea Mayer-Mokler (1)  ·  Andrew Gilman (1)  ·  Arnulf Stenzl, Prof. (1)  ·  B. Smith (1)  ·  Ba Yi (1)  ·  Brandon M. Triplett, MD (1)

Results publications

PMID 33986124, PMID 11359672, PMID 18809608, PMID 18833002, PMID 21525398, PMID 22495394, PMID 25126421, PMID 25454870, PMID 25688159, PMID 27190628, PMID 27879972, PMID 28851380, PMID 29863979, PMID 32439700, PMID 32513836, PMID 32554615, PMID 33831732, PMID 33942954, PMID 34046035, PMID 34484187, PMID 34773923, PMID 36089578, PMID 36248865, PMID 36326756, PMID 40132910, PMID 42728546

NIH funding

P30CA022453 (2), P30CA051008 (2), 2008 (1), 2009 (1), 2015 (1), 2017 (1), 2019 (1), 2023 (1), P01CA015396 (1), P30CA015083 (1), P30CA015704 (1), P30CA043703 (1), R01CA088972 (1), R01CA129517 (1)